Daiichi Sankyo announces initiation of Phase 3 Trial of mRNA

COVID-19 Vaccine (DS-5670) in Unvaccinated Individuals in Japan

Bayer initiates Phase III study program to investigate oral FXIa inhibitor asundexian

The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke

Biological E. announces CDSCO recommendation of its infant’s vaccine

Subject Expert Committee(SEC) of Central Drugs Standard Control Organization (CDSCO)

Merck India inaugurates R&D Excellence Centre in Bangalore

The Centre aims at promoting innovation among the scientific community to improve healthcare solutions around the globe

Alembic Pharmaceuticals receives USFDA Final Approval for Chlorthalidone Tablets

Chlorthalidone Tablets USP, 25 mg and 50 mg, have an estimated market size of US $37 million for twelve months ending June, 2022 according to IQVIA

Hikma launches seasonal allergic rhinitis nasal spray RYALTRIS in the US

This launch builds upon Hikma’s leading position as one of the largest US providers of nasally administered medicines used for treating seasonal allergies and advances its objective of growing its specialty business in the US

Cipla (EU) to acquire an additional 13.10% stake in Cipla (Jiangsu) Pharmaceutical

Post-acquisition, Cipla EU's stake in the subsidiary will increase to 93.10%.

Granules India receives ANDA approval for Loperamide Hydrochloride and Simethicone Tablets

Merck to present new data of oncology portfolio at ESMO 2022

Longer-term survival results underscoring role of KEYTRUDA (pembrolizumab) in multiple cancer types, including advanced nonsquamous non-small cell lung cancer (KEYNOTE-189)

KIMS Hospitals to acquire majority stake in Kingsway Hospitals, Nagpur

The existing hospital premises has the scope to further scale up the bed capacity as and when required in the future with minimal Capex.